Organization | Assembly Biosciences

Assembly Biosciences Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: Carmel IN United States (2005)

Organization Overview

First Clinical Trial

2016

NCT02908191

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Assembly Biosciences

Active Ingredients

Drugs in Phase 3 Trials (2)

Key: Assembly Biosciences (0) Acquired (2)

diltiazem (cardizem) (5 trials)

iferanserin (2 trials)

Drugs in Phase 2 Trials (9)

ab-729 (1 trial)

abi-h0731 (8 trials)

abi-h2158 (4 trials)

entecavir (baraclude) (6 trials)

etravirine (intelence) (2 trials)

interferon alpha-2a (roferon-a) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

tenofovir (viread) (5 trials)

tenofovir alafenamide (genvoya) (3 trials)

Drugs in Phase 1 Trials (13)

Key: Assembly Biosciences (10) Acquired (3)

abi-4334 (1 trial)

abi-h3733 (2 trials)

abi-m201 (1 trial)

clarithromycin (biaxin) (1 trial)

esomeprazole (nexium) (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

itraconazole (sporanox) (1 trial)

levonorgestrel (1 trial)

midazolam (versed) (1 trial)

rifampin (1 trial)

sodium chloride (2 trials)

sodium monododecyl sulfate (2 trials)

vebicorvir (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Colitis (Phase 1)

Colitis, Ulcerative (Phase 1)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis B (Phase 2)

Hepatitis B, Chronic (Phase 2)

Hepatitis, Chronic (Phase 2)

Ulcer (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 24
# of Trial APIs: 24